Nektar Therapeutics (NASDAQ:NKTR – Get Free Report) had its price objective raised by HC Wainwright to $120.00 in a research report issued on Tuesday, June 24th, MarketBeat reports. The firm presently has a “buy” rating on the biopharmaceutical company’s stock. HC Wainwright’s price target suggests a potential upside of 388.00% from the company’s current price. HC Wainwright also issued estimates for Nektar Therapeutics’ Q2 2025 earnings at ($2.68) EPS, Q3 2025 earnings at ($2.58) EPS, Q4 2025 earnings at ($2.62) EPS, FY2025 earnings at ($11.49) EPS, Q1 2026 earnings at ($3.00) EPS, Q2 2026 earnings at ($3.38) EPS, Q3 2026 earnings at ($3.06) EPS, Q4 2026 earnings at ($3.17) EPS, FY2027 earnings at ($12.17) EPS, FY2028 earnings at ($13.98) EPS and FY2029 earnings at ($7.24) EPS.
NKTR has been the topic of several other research reports. Wall Street Zen lowered shares of Nektar Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, May 14th. Oppenheimer raised Nektar Therapeutics from a “market perform” rating to an “outperform” rating and set a $90.00 price target on the stock in a research report on Friday, March 14th. Jefferies Financial Group upgraded Nektar Therapeutics from a “hold” rating to a “buy” rating and upped their price target for the stock from $15.00 to $30.00 in a research note on Friday, April 11th. Finally, William Blair reiterated a “market perform” rating on shares of Nektar Therapeutics in a research note on Monday, May 12th. One analyst has rated the stock with a sell rating, one has given a hold rating, five have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $84.17.
Check Out Our Latest Research Report on Nektar Therapeutics
Nektar Therapeutics Stock Performance
Nektar Therapeutics (NASDAQ:NKTR – Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The biopharmaceutical company reported ($3.30) EPS for the quarter, missing the consensus estimate of ($2.70) by ($0.60). The firm had revenue of $10.46 million for the quarter, compared to analysts’ expectations of $15.61 million. Nektar Therapeutics had a negative net margin of 152.49% and a negative return on equity of 329.54%. During the same period in the prior year, the business posted ($2.70) EPS. On average, analysts expect that Nektar Therapeutics will post -0.72 EPS for the current fiscal year.
Institutional Inflows and Outflows
Several hedge funds have recently modified their holdings of NKTR. Two Sigma Securities LLC increased its holdings in Nektar Therapeutics by 56.3% in the 4th quarter. Two Sigma Securities LLC now owns 27,654 shares of the biopharmaceutical company’s stock worth $26,000 after buying an additional 9,958 shares in the last quarter. Price T Rowe Associates Inc. MD grew its stake in shares of Nektar Therapeutics by 6.0% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 192,978 shares of the biopharmaceutical company’s stock worth $180,000 after acquiring an additional 10,941 shares during the period. Northern Trust Corp lifted its position in Nektar Therapeutics by 0.9% during the fourth quarter. Northern Trust Corp now owns 1,414,984 shares of the biopharmaceutical company’s stock valued at $1,316,000 after purchasing an additional 12,826 shares during the period. ProShare Advisors LLC boosted its holdings in Nektar Therapeutics by 49.0% in the fourth quarter. ProShare Advisors LLC now owns 50,277 shares of the biopharmaceutical company’s stock worth $47,000 after purchasing an additional 16,543 shares during the last quarter. Finally, Wells Fargo & Company MN grew its position in Nektar Therapeutics by 26.5% in the 4th quarter. Wells Fargo & Company MN now owns 108,975 shares of the biopharmaceutical company’s stock worth $101,000 after purchasing an additional 22,822 shares during the period. Hedge funds and other institutional investors own 75.88% of the company’s stock.
About Nektar Therapeutics
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer.
Further Reading
- Five stocks we like better than Nektar Therapeutics
- What is an Earnings Surprise?
- Toast Stock: A Fast-Growing Mid-Cap Eyeing Further Upside
- How to Plot Fibonacci Price Inflection Levels
- Breakout Alert: Disney Stock Hits Multi-Year High
- High Flyers: 3 Natural Gas Stocks for March 2022
- Forget IBM: Accenture’s AI Momentum Is Your Next Buy
Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.